glp 1 drugs muscle loss Glucagon-like peptide-1 receptor agonists and mass effects Some people taking GLP-1 weight

Ready to explore whether GLP-1 therapy is right for you

Tanokashira D, Fukuokaya W, Taguchi A

Our new Houston site will enhance Lillys ability to manufacture orforglipron at scale and, if approved, help fulfill the medicines potential as a metabolic health treatment for tens of millions of people worldwide who prefer the ease of a pill that can be taken without food and water restrictions, Lilly CEO David A

Abbreviations DPP-4: Dipeptidyl-peptidase 4 EXAMINE: Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care GLP-1: Glucagon-like peptide 1 PYO: Patient-year of exposure SAVOR-TIMI 53: The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)Thrombolysis in Myocardial Infarction (TIMI) 53 trial References Butler PC, Elashoff M, Elashoff R, Gale EA (2013) A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe